Targeted signal-amplifying enzymes enhance MRI of EGFR expression in an orthotopic model of human glioma

Cancer Research

Volumn 71, Issue 6, 2011, Pages 2230-2239

  Shazeeb, Mohammed S ^a   Sotak, Christopher H ^a   DeLeo III, Michael ^a   Bogdanov, Alexei ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CETUXIMAB; DITYRAMIDO GADOLINIUM PENTETATE; EPIDERMAL GROWTH FACTOR RECEPTOR; GADOLINIUM PENTETATE; GLUCOSE OXIDASE; HORSERADISH PEROXIDASE; MATUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL VIABILITY; CONJUGATION; CONTROLLED STUDY; ENZYME SYNTHESIS; GLIOMA; HISTOPATHOLOGY; IMAGE ANALYSIS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAGNETIC FIELD; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOMERIZATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

EID: 79952769291     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1139     Document Type: Article

References (43)

1. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990;50:8017-22.
2. Sauter G, Maeda T, Waldman FM, Davis RL, Feuerstein BG. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol 1996;148:1047-53. (Pubitemid 26108242)
3. Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification- rearrangement in human glioblastomas. Int J Cancer 1995;62:145-8.
4. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002;110:669-72. (Pubitemid 35283957)
5. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-70. (Pubitemid 37322983)
6. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994;9:2313-20. (Pubitemid 24228682)
7. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994;91:7727-31. (Pubitemid 24238258)
8. Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 2005;1:221-34.
9. Wagner TD, Yang GY. Cetuximab: its use in combination with radiation therapy and chemo-therapy in the multimodality treatment of head and neck cancer. Recent Pat Anticancer Drug Discov 2008;3:76-83.
10. Weber J, McCormack PL. Panitumumab: in metastatic colorectal cancer with wild-type KRAS. BioDrugs 2008;22:403-11.
11. Gleysteen JP, Newman JR, Chhieng D, Frost A, Zinn KR, Rosenthal EL. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck 2008;30:782-9. (Pubitemid 351913856)
12. Koyama Y, Barrett T, Hama Y, Ravizzini G, Choyke PL, Kobayashi H. In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia 2007;9:1021-9.
13. Adams KE, Ke S, Kwon S, Liang F, Fan Z, Lu Y, et al. Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 2007;12:024017.
14. Diagaradjane P, Orenstein-Cardona JM, Colon-Casasnovas NE, Deorukhkar A, Shentu S, Kuno N, et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res 2008;14:731-41. (Pubitemid 351231154)
15. Nunn AD, Linder KE, Tweedle MF. Can receptors be imaged with MRI agents?Q J Nucl Med 1997;41:155-62.
16. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2003;2:123-31. (Pubitemid 37361644)
17. De Leon-Rodriguez LM, Lubag AJ, Malloy CR, Martinez GV, Gillies RJ, Sherry AD. Responsive MRI agents for sensing metabolism in vivo. Acc Chem Res 2009;42:948-57.
18. Cerdan S, Lotscher HR, Kunnecke B, Seelig J. Monoclonal antibody-coated magnetite particles as contrast agents in magnetic resonance imaging of tumors. Magn Reson Med 1989;12:151-63. (Pubitemid 19271503)
19. To SY, Castro DJ, Lufkin RB, Soudant J, Saxton RE. Monoclonal antibody-coated magnetite particles as contrast agents for MR imaging and laser therapy of human tumors. J Clin Laser Med Surg 1992;10:159-69.
20. Remsen LG, McCormick CI, Roman-Goldstein S, Nilaver G, Weissleder R, Bogdanov A, et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. AJNR Am J Neuroradiol 1996;17:411-8. (Pubitemid 26101942)
21. Suwa T, Ozawa S, Ueda M, Ando N, Kitajima M. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int J Cancer 1998;75:626-34. (Pubitemid 28094112)
22. Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang X, et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 2009;5:235-43.
23. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultra-sensitive drug delivery systems. Nano Lett 2006;6:2427-30.
24. Kobayashi H, Brechbiel MW. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev 2005;57:2271-86. (Pubitemid 41759396)
25. Netti PA, Hamberg LM, Babich JW, Kierstead D, Graham W, Hunter GJ, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A 1999;96:3137-42. (Pubitemid 29148857)
26. Neuwelt EA, Specht HD, Hill SA. Permeability of human brain tumor to 99mTc-gluco-heptonate and 99mTc-albumin. Implications for monoclonal antibody therapy. J Neurosurg 1986;65:194-8. (Pubitemid 16057491)
27. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003;49:403-8. (Pubitemid 36262806)
28. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003;63:2723-7. (Pubitemid 36667139)
29. Zhu W, Okollie B, Bhujwalla ZM, Artemov D. PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med 2008;59:679-85. (Pubitemid 351501930)
30. Bogdanov A Jr., Kang HW , Querol M , Pretorius PH , Yudina A . Synthesis and testing of a binary catalytic system for imaging of signal amplification in vivo. Bioconjug Chem 2007;18:1123-30. (Pubitemid 47122633)
31. Bogdanov A Jr., Matuszewski L, Bremer C, Petrovsky A, Weissleder R. Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets. Mol Imaging 2002;1:16-23.
32. Querol M, Bennett DG, Sotak C, Kang HW, Bogdanov A Jr. A paramagnetic contrast agent for detecting tyrosinase activity. Chembiochem 2007;8:1637-41. (Pubitemid 47523663)
33. Ichikawa T, Hogemann D, Saeki Y, Tyminski E, Terada K, Weissleder R, , et al. MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia 2002;4:523-30. (Pubitemid 35417076)
34. Sena-Esteves M, Saeki Y, Camp SM, Chiocca EA, Breakefield XO. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol 1999;73:10426-39.
35. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984;44:1002-7. (Pubitemid 14152782)
36. Rasband WS, Image J, U. S. National Institutes of Health, Bethesda, Maryland, USA, 1997-2011. http://imagej.nih.gov/ij/.
37. Petrovsky A, Schellenberger E, Josephson L, Weissleder R, Bogdanov A Jr. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 2003;63:1936-42. (Pubitemid 36460861)
38. Reimer P, Weissleder R, Lee AS, Wittenberg J, Brady TJ. Receptor imaging: application to MR imaging of liver cancer. Radiology 1990;177:729-34.
39. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, et al. In vivo magnetic resonance imaging of transgene expression. Nat Med 2000;6:351-5.
40. Querol M, Bogdanov A Jr. Amplification strategies in MR imaging: activation and accumulation of sensing contrast agents (SCAs). J Magn Reson Imaging 2006;24:971-82. (Pubitemid 44658232)
41. Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, et al. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 2008;7:726-33.
42. Rodriguez E, Nilges M, Weissleder R, Chen JW. Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity. J Am Chem Soc 2009;132:168-77.
43. JuanYin J, Tracy K, Zhang L, Munasinghe J, Shapiro E, Koretsky A, et al. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis 2009;26:403-14.